|Rapid Review Complete
|Insulin degludec/liraglutide (IDegLira)
|For the treatment of adults with type 2 diabetes mellitus (T2DM) to improve glycaemic control in combination with oral glucose-lowering medicinal products when these alone or in combination with a Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) or basal insulin does not provide adequate glycaemic control.
|Rapid review commissioned
|Rapid review completed
|Rapid review outcome
|Full pharmacoeconomic assessment recommended at the submitted price.
The HSE has approved reimbursement; July 2019.